3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1/2
5
Phase 1
5
Phase NA
3
Phase 3
3
Phase 4
2
Phase EARLY_PHASE1
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
1129
Carcinoma, Non-Small-Cell Lung
718
Neoplasms
546
Prostatic Neoplasms
505
Colorectal Neoplasms
439
Multiple Myeloma
338
Lung Neoplasms
310
Neoplasm Metastasis
289
Leukemia, Myeloid, Acute
263
Stomach Neoplasms
248
Carcinoma, Hepatocellular
246
Ovarian Neoplasms
225
Rectal Neoplasms
211
Colonic Neoplasms
204
Lymphoma, Follicular
200
Lymphoma
199
Leukemia
190
Uterine Cervical Neoplasms
181
Head and Neck Neoplasms
174
Pancreatic Neoplasms
172
Lymphoma, Non-Hodgkin
167
Leukemia, Lymphocytic, Chronic, B-Cell
166
Lymphoma, Large B-Cell, Diffuse
163
Recurrence
162
Melanoma
158
Precursor Cell Lymphoblastic Leukemia-Lymphoma
154
Squamous Cell Carcinoma of Head and Neck
147
Pain
141
Urinary Bladder Neoplasms
139
Brain Neoplasms
133
Interventions
Sirolimus
2
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Interventional
×
Lymphangioleiomyomatosis
×
Clear all
NCT03150914
2024-12-24
MILED
University of Cincinnati
Phase 3
Active not recruiting
60 enrolled
NCT00414648
2023-11-02
MILES
University of Cincinnati
Phase 3
Completed
89 enrolled
15 charts
NCT00790400
2017-02-17
EXIST-2
Novartis
Phase 3
Completed
118 enrolled
15 charts